The consideration is INR 2800 million (SEK 351 million) on a cash and debt free basis whereof INR 600 million (SEK 75 million) will be paid in newly issued Recipharm shares (RECI-B).
The acquisition will be completed in two steps; the cash part on 2 January and the part paid in Recipharm shares later during the first half of 2018.
Thomas Eldered, CEO of Recipharm said: “I have been particularly pleased with the way the performance in Nitin Lifesciences has developed after it became part of the Recipharm Group. Both sales and margins have grown in the business despite the recent macro-economic volatility in India and we foresee this favourable development to continue.”
“The transaction will allow us to combine and better exploit operational synergies with our other Indian business. The equity investment will align interests of the Sobti family. As such, I have great pleasure in announcing that current chief executives and members of the founding family Dr Chetan Sobti and Mr Nitin Sobti shall not only continue to spearhead the current business but also in addition take on the responsibility to develop and grow Recipharm’s total business in the Indian and emerging markets.”
